Rasio rega marang prakiraan pendapatan PepGen (PEPG)
PepGen Inc. develops drugs for the treatment of neuromuscular pathologies, demonstrating complete independence from economic cycles. The development strategy relies on finding a strategic ally among industry behemoths. The expected market cap-to-revenue ratio clearly captures market expectations, where the parameter value reaches . However, the high density of scientific research in the RNA sector creates significant competitive risks.
Rincian metrik keuangan lan pasar pepgen.com (PEPG)
- rega saiki lan proyeksi nilai saham:
- rincian kapitalisasi pasar:
- indikator nilai buku ekuitas:
- indikator total utang lan likuiditas perusahaan:
- rincian asil keuangan lan kelipatan valuasi:
PEPG - Bathi perusahaan|Proyeksi bathi mangsa ngarep PepGen Inc.|PEPG - Kapitalisasi marang bathi|Prakiraan rega marang bathi PepGen|PEPG - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan PepGen Inc.|PEPG - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan PepGen|PEPG - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan pepgen.com|PEPG - Dinamika bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep PepGen Inc.
- data dodolan lan asil:
Analisis wiwitan perusahaan:PEPG (PepGen Corp)
The forward P/S ratio assesses the market value of PepGen Inc. (PEPG) relative to expected sales volume, making it possible to determine the extent of asset overvaluation during periods of revenue stagnation. Analyzing the forward P/S chart for PepGen Inc. (PEPG) helps correlate the multiplier's dynamics with the potential of the EDO platform, where a contraction of the metric amid the success of Phase 2 clinical trials could signal that PepGen Inc. (PEPG) is undervalued prior to its market entry.
Pesaing langsung
Multiplikator Forward P/S BIIB (Biogen)|Rasio kapitalisasi marang dodolan sing dikarepake Neurocrine (NBIX)|RGC - Rasio rega marang prakiraan pendapatan|AXSM (Axsome Corp) - Kapitalisasi marang prakiraan pendapatan|ACAD: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan xenon-pharma.com|Multiplikator forward rega marang pendapatan VKTX|Supernus Pharmaceuticals, Inc. (SUPN) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Catalyst Pharmaceuticals Inc (CPRX)|DNLI: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S HRMY (Harmony Biosciences)|biohavenpharma.com (BHVN) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|AMLX - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan TRVI|PRAX: Multiplikator Forward P/S|Prakiraan rega marang pendapatan Anavex Life Sciences Corp AVXL|Rasio rega marang prakiraan pendapatan CeriBell, Inc.|Kapitalisasi marang prakiraan pendapatan PRTA (Prothena Corporation)|Multiplikator Forward P/S ALEC|ANNX - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Omeros - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Neurogene Therapeutics NGNE|ACIU - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan VYGR (voyagertherapeutics.com)|Neumora Therapeutics, Inc. (NMRA) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Scilex Holding (SCLX)|Rasio rega marang prakiraan pendapatan Tevogen Bio Holdings, Inc.|Alpha Cognition Corp - Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S CGTX|IKT - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Cassava Sciences SAVA|ASRT (Assertio Holdings) - Rega mangsa ngarep marang pendapatan|Coya - Multiplikator Forward P/S|Prakiraan rega marang pendapatan Vistagen Therapeutics (VTGN)|OVID: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep acumenpharm.com (ABOS)|Rasio rega marang prakiraan pendapatan CervoMed|Kapitalisasi marang prakiraan pendapatan ATHE (Alterity Therapeutics Ltd)|Multiplikator forward rega marang pendapatan CLNN (Clene Inc.)|JUNS (Jupiter Neurosciences, Inc.) - Rega forward marang dodolan|Multiplikator Forward P/S RLMD (Relmada Therapeutics)|Rasio kapitalisasi marang dodolan sing dikarepake annovisbio.com (ANVS)|GRCE - Rasio rega marang prakiraan pendapatan|AIFF (Firefly Neuroscience, Inc.) - Kapitalisasi marang prakiraan pendapatan|KLTO: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan NeuroSense Therapeutics Ltd.|Multiplikator forward rega marang pendapatan RVPH|MetaVia, Inc. (MTVA) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan NeurAxis (NRXS)|HSDT: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S PASG (Passage Bio)|Neuphoria Therapeutics, Inc. (NEUP) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|NERV - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan ATHA|ADXN: Multiplikator Forward P/S|Prakiraan rega marang pendapatan Alzamend Neuro ALZN|Rasio rega marang prakiraan pendapatan Cyclerion Therapeutics Inc.|Kapitalisasi marang prakiraan pendapatan PTIX (Protagenic)|Multiplikator Forward P/S KTTA|CRGT - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Avenue Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Brainstorm Cell Therapeutics Inc. BCLI|CARA - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan CHRO (Chromocell)|eliemtx.com (ELYM) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Intra-Cellular Therapies, Inc. (ITCI)|Rasio rega marang prakiraan pendapatan Longboard Pharmaceuticals, Inc.|Marinus Pharmaceuticals Inc - Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S NKGN|NRBO - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Sage Therapeutics, Inc. SAGE|SNPX (synaptogen.com) - Rega mangsa ngarep marang pendapatan|Trevena - Multiplikator Forward P/S|Prakiraan rega marang pendapatan Vigil Neuroscience (VIGL)|WENA: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Cerevel Corp (CERE)
